Switching Kids with Severe Pneumonia to Pills Sooner Sent Them Home a Day Earlier, Large Trial Finds

What the report says

Medical Daily reported that a large PediCAP trial found children hospitalized with severe community-acquired pneumonia could be moved from intravenous antibiotics to oral treatment after clinical improvement without worse short-term outcomes. The study, published in The Lancet and summarized by CIDRAP, enrolled 1,101 children aged two months to six years at 13 hospitals in South Africa, Uganda, Zambia, Zimbabwe and Mozambique.

Researchers compared two oral “step-down” strategies — amoxicillin and amoxicillin-clavulanate — with the standard approach of completing five days of injectable antibiotics, which aligns with current World Health Organization guidance for severe childhood pneumonia. The trial’s main measure was readmission or death from any cause within 28 days. Medical Daily reported rates of 5.6% for oral amoxicillin, 6.9% for oral amoxicillin-clavulanate and 6.3% for IV-only treatment, meeting the study’s non-inferiority threshold. Adverse events were similar across groups.

The step-down groups received a median of two days of IV antibiotics and had median hospital stays of 5.5 days, compared with 6.5 days for children kept on IV therapy. The report also noted no advantage for broader-spectrum amoxicillin-clavulanate over amoxicillin, a finding relevant to cost, access and antimicrobial stewardship.

The findings matter most for hospitals using WHO-guided protocols in resource-limited settings, where prolonged inpatient IV treatment can strain beds and impose costs on families. Medical Daily cautioned that the trial does not directly describe U.S. pediatric practice, where earlier oral switching is already common in many hospitals, and that treatment decisions still depend on each child’s condition and clinical response.